The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
Francesco GiorginoBruno GuerciMartin FüchtenbuschJérémie LebrecKristina S BoyeMarco Orsini FedericiElke HeitmannAnne DibMaria YuHélène SapinLuis-Emilio Garcia-PerezPublished in: Diabetes, obesity & metabolism (2023)
Dulaglutide-initiating patients had a longer time spent without any significant treatment change and higher persistence than those initiating liraglutide. Treatment with either glucagon-like peptide-1 receptor agonist yielded similar and clinically meaningful reductions in HbA1c and body weight.